Biotech Values

[DewDiligence]

AGN:

Not sure how important this formulation is…

All of the major dermal fillers either have lidocaine already or will soon have it, so AGN’s FDA approval of Juvederm with lidocaine was important from a competitive standpoint.

--
p.s. Merz’s acquisition of BFRM closes this week. Here’s a question to ponder: Will Merz now become a buyout target in its own right? I originally thought JNJ would end up owning BFRM at some point and they still could—by buying Merz.